linjc16/ctgov huggingface dataset:
Aspirin Resistance Following Coronary Bypass Surgery

Study Overview
=================
Brief Summary
-----------------
Aspirin was proved to be the drug preventing vein grafts from closure and improving clinical outcome after coronary artery bypass surgery. It appears to be effective when being prescribed as early as first 48 hr. after the operation without increasing the incidence of bleeding complications. the exact effective dose is not known.

Conditions
-----------------
Ischemic Heart Disease

Intervention / Treatment
-----------------
* Procedure: Coronary artery bypass surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing Coronary artery bypass surgery Patients who signed Informed Consent Form Exclusion Criteria: Concomitant valve surgery or carotid surgery or off-pump surgery Need for anticoagulation therapy for any reason Another antiplatelet medications at least 7 days prior to surgery Contra-indication for aspirin treatment Thrombocytopenia / thrombocytopathia NSAIDs treatment for chronic medical conditions Reluctance to participate in the study

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Coronary artery bypass surgery|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ventilation |  |  | 
| Inotropic support |  |  | 
| Mortality |  |  | 
| Perioperative MI |  |  | 
| Perioperative stroke |  |  | 
| Bleeding / reopen / transfusion |  |  | 
| Dysrhythmias |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ICU stay |  |  | 
| In-hospital stay |  |  | 
| Non-fatal cardiac events - MI, recurrence of angina, dysrhythmias |  |  | 
| Need for repeat revascularization |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Aspirin treatment, Aspirin resistance, Coronary bypass surgery
Prospective Data Collection of Patients Undergoing Gynecologic Surgery

Study Overview
=================
Brief Summary
-----------------
The aim of this prospective study is to collect data on patients undergoing gynecologic surgery at Kangbuk Samsung Hospital.

Detailed Description
-----------------
The aim of this prospective study is to collect data on patients undergoing gynecologic surgery at Kangbuk Samsung Hospital. If patients agree to participate in this clinical trial, patient's data (such as age, body mass index, preoperative findings, laboratory findings, radiologic findings, operative findings, pathologic findings, postoperative findings) will be collected in a research database. The research database will be updated, every 6 month, to include data on patient's disease outcome and follow-up care. Although most data will be collected form the medical record, patient may agin be contacted so that researchers can collection some data if it is not in the medical record.

Official Title
-----------------
Prospective Data Collection of Patients Undergoing Gynecologic Surgery

Conditions
-----------------
Disease (or Disorder); Gynecological

Intervention / Treatment
-----------------
* Procedure: Gynecologic surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients undergoing gynecologic surgery at Kangbuk Samsung Hospital since March, 2015 Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Gynecologic surgery|The researchers prospectively will collect data on all patients undergoing gynecologic surgery at Kangbuk Samsung Hospital since March, 2015.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prospective data collection of patients undergoing gynecologic surgery |  | 10 years |
Electronic Catheter Stethoscope

Study Overview
=================
Brief Summary
-----------------
This is an observational, exploratory study designed to collect (record) and analyze normal and abnormal sound data from the human bladder during surgery using a novel sensor-based catheter system (Electronic Catheter Stethoscope) and to develop algorithms to detect changes of baseline bladder and ureteral function. The Electronic Catheter Stethoscope device will measure acoustic and pressure data within the bladder. The measurements will be used to detect any leakage from the bladder and/or changes in baseline ureteral flow by correlation of sound data with surgical data reported by the surgeon. These data will be used to develop algorithms to detect changes of baseline bladder and ureteral function. The algorithms will be tested in future clinical trials.

Official Title
-----------------
Use of the Electronic Catheter Stethoscope for the Detection of Urinary Tract Injury During Gynecologic Surgery

Conditions
-----------------
Pelvic Organ Prolapse, Gynecologic Cancers, Uterine Leiomyomata, Adenomyosis, Endometrial Hyperplasia, Other Abnormal Uterine and Vaginal Bleeding, Pelvic Mass, Pelvic Pain

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria age 18 or older plan to have one of the following types of surgery: laparoscopic or abdominal gynecological surgery vaginal surgery able to provide written informed consent Exclusion Criteria under 18 years of age bilateral tubal ligation as the single reason for surgery current pregnancy unable to provide written informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Electronic Catheter Stethoscope<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| bladder and ureter sounds during pelvic surgery. |  | from time of bladder catheter placement and initiation of recording during surgery to completion of pelvic surgery (within 8 hours) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| changes from baseline bladder and ureteral function sounds |  | from time of bladder catheter placement and initiation of recording during surgery to completion of pelvic surgery (within 8 hours) |
Impact of Echinacea as Prophilaxis for Upper Respiratory Tract Infections in Children 1-5 Years

Study Overview
=================
Brief Summary
-----------------
Acute upper respiratory tract infections are the most commmon infections in children and are associated with complications such as acute otitis media, sinusitis and pneumonia. Echinacea is widely used for treatment of upper respiratoty tract infections. The aim of this study is to evaluate its efficacy as prophilaxis in children 1-5 years old.

Official Title
-----------------
Impact of Echinacea as Prophilaxis for Upper Respiratory Tract Infections in Children 1-5 Years in Bandarabbas Children' Hospital

Conditions
-----------------
Upper Respiratory Tract Infections

Intervention / Treatment
-----------------
* Drug: Echinacea
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Childrens 1-5 years old Exclusion Criteria: Wheezing in previous 3 months requiring bronchodilatator History of hyperactive reactive airway using steroid or Echinacea chronic pulmonary of cardiac disease Acute respiratory disease within one week before study Allergic rhinitis Allergy to Echinacea avoiding to participate in the study

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 5 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Echinacea<br>0.5ml daily for children 1-2 years old and 2ml daily for children2-5 years old for 3 months | Drug: Echinacea<br>* 0.5ml daily for children 1-2 years old and 2ml daily for children 2-5 years old<br>* Other names: American Cone Flower;|
| Placebo Comparator: Placebo<br>Placebo | Drug: Placebo<br>* Placebo (0.5ml daily for children 1-2 years old and 2ml daily for children 2-5 years old) for 3 months<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| occurrence of upper respiratory tract infection diagnosed by physician according to history and physical examination and laboratory tests if was necessary |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Drug side effects |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Upper Respiratory Tract Infections, Echinacea, viral infections
Biomarkers of Early Chronic Obstructive Pulmonary Disease (COPD) in Smokers - Longitudinal Study

Study Overview
=================
Brief Summary
-----------------
This is a longitudinal observational study to identify and validate protein biomarkers for COPD (chronic obstructive pulmonary diseases) and cardiovascular disease in smokers and ex-smokers attending primary care. Special emphasize is to correlate biomarkers to different phases of COPD, to progression of the disease, and to treatment of the disease. Furthermore, linkage between COPD, cardiovascular disease, and lung cancer will be investigated by identifying protein biomarkers.

Official Title
-----------------
Biomarkers of Early Chronic Obstructive Pulmonary Disease (COPD) and Cardiovascular Diseases in Smokers/Ex-Smokers Attending Primary Care - Longitudinal Study

Conditions
-----------------
Chronic Obstructive Pulmonary Disease, Cardiovascular Disease, Lung Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed with COPD Gold stage 0-IV Exclusion Criteria: Patients with inflammatory diseases Patients with cancer Patients using immune system regulating drugs

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| GOLD stage I<br> | |
| GOLD Stage II<br> | |
| GOLD Stage III<br> | |
| GOLD Stage IV<br> | |
| Smokers/ex-smokers w/o COPD<br> | |
| non-Smokers w/o COPD<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Advanced disease etiology requiring hospitalization. |  | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COPD, Primary Care, Smoking, Smokers, ex-Smokers, Lung Cancer, Cardiovascular Disease, Proteomics, Biomarkers, Biobank, Disease Staging, Gold Stage
Lipofilling: Optimal Harvesting Techniques for Breast Reconstruction After Mastectomy in Plastic Aesthetic and Reconstructive Surgery

Study Overview
=================
Brief Summary
-----------------
The primary aim of this project is to standardize the method for lipofilling by identifying the best technique. In this context, the study will investigate the impact of adipose tissue composition and ideal quantity of the injected fat particularly in view of resorption rate. Correlations between adipose tissue composition, amount of transferred fat, already existing subcutaneous fat layer at the grafting site and resorption rate will be made. The punch biopsy and the non-invasive Lipometer measurements to determine the subcutaneous fat layer thickness in the harvesting and grafting region will be performed in 10 female subjects that undergo elective lipofilling. The study was registered on Clinicaltrials.gov after start of recruitment.

Official Title
-----------------
Lipofilling: Optimal Harvesting Techniques for Breast Reconstruction After Mastectomy in Plastic Aesthetic and Reconstructive Surgery - a Pilot Study

Conditions
-----------------
The Impact of Adipose Tissue Quality on Fat Graft Retention

Intervention / Treatment
-----------------
* Procedure: fat grafting


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women, age 18-70 years (limited upwards due to the indication for lipofilling and the amount of possible secondary diseases) History of BRCA1 and BRCA2 - positive breast cancer with following subcutaneous mastectomy Planned, elective breast-lipofilling Thickness of the skin and subcutaneous fat layer of min. 1 cm (detected via sonography) Currently healthy individual, willing to participate in this study Exclusion Criteria: Previous surgery at the harvesting site (e.g. caesarian section) Pregnancy or planned pregnancy Current or preceded chemotherapy Preceded radiatio Unable to fully understand study procedures and to provide informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: fat grafting|Fat will be removed from abdomen or legs, processed and re-injected into grafting sites.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adipose tissue dependent take rate | Detect an adipose tissue composition-dependent take rate | 12-24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
fat graft, adipose tissue
ARROW:identificAtion of postpRandial biomaRkers tOWards Cardiovascular Prevention

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to better understand the association between the postprandial biomarker responses after a food challenge with the development of cardiovascular diseases in healthy subjects

Official Title
-----------------
ARROW: identificAtion of postpRandial biomaRkers tOWards Cardiovascular Prevention

Conditions
-----------------
Cardiovascular Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Willing and able to sign written informed consent in English or Chinese prior to trial entry 40-54 years old Both male and female subjects Chinese ethnic group (having both grandparents Chinese) Low Framingham risk of CHD (<10%) Apparently healthy (i.e. no chronic or ongoing acute disease), based on investigator's clinical judgement Exclusion Criteria: Food allergy to any of the constituents of the meal challenge (milk proteins, lactose, soy). Subjects not willing or not able to comply with scheduled visits and the requirements of the study protocol. Contraindication to MRI Pregnant or lactating women based on investigator's clinical judgement. Morbid obesity (BMI ≥ 40 kg/m2). Previous myocardial infarction (MI). This will include ST-elevation MI (STEMI) and non-ST-elevation MI (NSTEMI). Known coronary artery disease - prior coronary revascularization. Known documented peripheral arterial disease. Previous stroke (defined as new focal neurological deficit persisting more than 24hours). Use of anti-hypertensive agents. Prior history of cancer (excludes pre-cancerous lesions). Life expectancy less than 1 year. Known definite diabetes mellitus or on treatment for diabetes mellitus. Known autoimmune disease or genetic disease. Known endocrine and metabolic diseases, even on treatment, including hyperlipidemia. Psychiatric illness. Asthma or chronic lung disease requiring long term medications or oxygen. Chronic infective disease, including tuberculosis, hepatitis B and C; and HIV. Currently participating or having participated in another clinical trial within 4 weeks prior to trial start (except for Biobank Study and SingHeart).

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 54 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| subject with plaques and without plaques<br>Subject with plaques and without plaques | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To compare the kinetics of postprandial biomarkers between two groups of healthy subjects with and without subclinical atherosclerosis |  | Within 28 days from enrollment |
Infection Rate of Vertical Expandable Prosthetic Titanium Rib Implants (VEPTR)

Study Overview
=================
Brief Summary
-----------------
The study is conducted to analyse the infection rate in children treated with VEPTR-Implants for severe spine or thoracic deformities.

Detailed Description
-----------------
Spinal and thoracic deformities in children can be treated with vertical expandable prosthetic titanium ribs (VEPTR©, Synthes GmbH®) to stimulate thoracic and spinal growth. With these implants children's symptoms and conditions can be slowed, halted or even reversed. Because of the dynamic character of the deformity and the growth of the children, the implants have to be lengthened about every half a year. With each operation there is a small risk of infection, which might increase with number of previous surgeries. Implant associated infections are often not clinical apparent and only found in microbiological analysis. To objectify the infection rate, identify potential precursors of infections and the relevance of asymptomatic infections in children with these implants a prospective study is conducted.

Official Title
-----------------
Infection Rate of VEPTR-Implants in Children With Severe Spinal and Thoracic Deformities

Conditions
-----------------
Infection

Intervention / Treatment
-----------------
* Device: Microbiological analysis of retained VEPTR Implants


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all patients admitted at the University Children's Hospital Basel in whom a VEPTR©-implant or parts of it will be removed. Exclusion Criteria: obvious contamination of an explanted component occurred in the operating room.

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| VEPTR patients<br>Children treated with VEPTR Implants for severe spinal or thoracic deformities | Device: Microbiological analysis of retained VEPTR Implants<br>* Implants have to be adapted every half a year, the retained implants during revision are analysed for biological colonization.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Infection rate of VEPTR Implants |  | two years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Infection rate of VEPTR-Implants, VEPTR. Vertical Expandable, Prosthetic Titanium Rib
The Foot in Your Nose Study: Links Between Nasal Staphylococcus Aureus Colonies and Diabetic Foot Lesion Infections

Study Overview
=================
Brief Summary
-----------------
The presence of S aureus in the nasal passages of diabetic patients may be a risk factor for diabetic foot lesion infections. Our aim is to compare the genetic profiles of S aureus strains found in the noses and on the foot lesions of diabetic patients. The investigators are also studying the virulence of these strains, the prevalance of S aureus at either site, and whether or not the quantity of S aureus found in the nose affects the risk for infection in foot lesions. The investigators also use this study to test the sensitivity and specificity of the GeneXpert system.

Official Title
-----------------
The Foot in Your Nose Study: Links Between Nasal Staphylococcus Aureus Colonies and Diabetic Foot Lesion Infections

Conditions
-----------------
Diabetic Foot, Staphylococcus Aureus

Intervention / Treatment
-----------------
* Biological: Genetic profiling of bacterial cultures


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 1 or 2 diabetic patients Patients consulting or hospitalized in the Diabetology departments of one of the participating centers Grade 2-4 ulcer on the foot or ankle (both primo and recurrent events are acceptable) Exclusion Criteria: Patient refuses to participate Pregnant, parturient or breastfeeding women Patient does not have diabetic foot or arteritic Diabetic ulcer is located elsewhere than the foot or ankle The ulcer is non-swabbable Patient does not have social-security coverage Patient is under any type of guardianship

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| All patients<br>All patients | Biological: Genetic profiling of bacterial cultures<br>* Genetic profiling of bacterial cultures harvested from both the nose and foot lesions of patients<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Presence/absence of the same S. aureus genetic profile in the nose and on the foot lesion. | Presence/absence of the same S. aureus genetic profile in the nose and on the foot lesion. Genetic profiles do not change with time. This is a transversal, pinpoint measure. | 3 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Diabetic foot